Biotech Acquisition Co Stock Current Valuation
| BIOTDelisted Stock | USD 10.15 0.00 0.00% |
Valuation analysis of Biotech Acquisition helps investors to measure Biotech Acquisition's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Biotech Acquisition's price fluctuation is very steady at this time. Calculation of the real value of Biotech Acquisition is based on 3 months time horizon. Increasing Biotech Acquisition's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Biotech Acquisition's intrinsic value may or may not be the same as its current market price of 10.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.15 | Real 8.66 | Hype 10.15 | Naive 10.13 |
The intrinsic value of Biotech Acquisition's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotech Acquisition's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biotech Acquisition Co helps investors to forecast how Biotech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotech Acquisition more accurately as focusing exclusively on Biotech Acquisition's fundamentals will not take into account other important factors: Biotech Acquisition Co Company Current Valuation Analysis
Biotech Acquisition's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biotech Acquisition Current Valuation | 290.09 M |
Most of Biotech Acquisition's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotech Acquisition Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Biotech Acquisition Co has a Current Valuation of 290.09 M. This is 99.12% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The current valuation for all United States stocks is 98.26% higher than that of the company.
Biotech Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotech Acquisition's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotech Acquisition could also be used in its relative valuation, which is a method of valuing Biotech Acquisition by comparing valuation metrics of similar companies.Biotech Acquisition is currently under evaluation in current valuation category among its peers.
Biotech Fundamentals
| Return On Asset | -0.0085 | |||
| Current Valuation | 290.09 M | |||
| Shares Outstanding | 23 M | |||
| Shares Owned By Institutions | 100.00 % | |||
| Number Of Shares Shorted | 9.3 K | |||
| Price To Earning | 29.21 X | |||
| Price To Book | 1.33 X | |||
| EBITDA | (6.86 M) | |||
| Net Income | (6.86 M) | |||
| Cash And Equivalents | 1.7 K | |||
| Total Debt | 153.35 K | |||
| Debt To Equity | 3.48 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.46) X | |||
| Cash Flow From Operations | (1.47 M) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | 0.26 X | |||
| Market Capitalization | 291.81 M | |||
| Total Asset | 230 | |||
| Net Asset | 230 |
About Biotech Acquisition Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotech Acquisition Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotech Acquisition using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotech Acquisition Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Biotech Stock
If you are still planning to invest in Biotech Acquisition check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotech Acquisition's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |